Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 17/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 13/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 12/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631333 | 0.87 | SMN1; SMN2 (0.41) | SMN1; SMN2HRH1ADRA1AADRA1B | |
| SCHEMBL6810247 | 0.87 | SMN1; SMN2 (0.41) | SMN1; SMN2HRH1ADRA1AADRA1B | |
| SCHEMBL6802422 | 0.83 | HRH1 (0.44) | HRH1ADRA1AADRA1BHRH3KCNH2 | |
| SCHEMBL6629463 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2KCNH2 | |
| SCHEMBL6806280 | 0.80 | HRH1 (0.39) | SMN1; SMN2HRH1ADRA1AADRA1BHRH3 | |
| SCHEMBL28038421 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2 | |
| SCHEMBL6629811 | 0.77 | SMN1; SMN2 (0.48) | SMN1; SMN2 | |
| SCHEMBL3579717 | 0.76 | SMN1; SMN2 (0.52) | SMN1; SMN2 | |
| SCHEMBL6357080 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2 | |
| SCHEMBL28038719 | 0.74 | SMN1; SMN2 (0.56) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064990-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | SMN1; SMN2 2159/4885HRH1 592/4885ADRA1A 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.